PAVmed(US:PAVM) Benzinga·2026-01-21 17:15Market Overview - U.S. stocks showed mixed performance with the Dow up 0.30% to 48,632.75, the S&P 500 rising 0.16% to 6,807.83, while the Nasdaq fell 0.06% to 22,940.77 [1] - European shares were also mixed, with the eurozone's STOXX 600 gaining 0.03% and Germany's DAX falling 0.47% [8] - Asian markets closed mixed, with Japan's Nikkei down 0.41% and Hong Kong's Hang Seng Index up 0.37% [11] Sector Performance - Energy shares increased by 2% on Wednesday, while consumer staples stocks dipped by 0.5% [2] Company Earnings - Johnson & Johnson reported fourth-quarter earnings of $2.46 per share, a 20.6% increase year-over-year, surpassing the consensus estimate of $2.44 [3] - The company also reported sales of $24.56 billion, up 9.1% year-over-year, exceeding the consensus of $24.16 billion [3] - For fiscal 2026, Johnson & Johnson provided adjusted earnings guidance of $11.43-$11.63, slightly above the consensus of $11.45, and expects sales of $99.50 billion-$100.5 billion compared to the consensus of $98.89 billion [4] Notable Stock Movements - PAVmed Inc shares surged 246% to $21.43 after a contract award for its EsoGuard Esophageal DNA Test [10] - Progress Software Corp shares rose 22% to $47.08 following better-than-expected fourth-quarter results and positive guidance [10] - Lisata Therapeutics Inc shares increased by 86% to $4.01 after announcing a binding term sheet for acquisition [10] - Venus Concept Inc shares dropped 55% to $1.99 due to plans to delist from Nasdaq [10] - Gibraltar Industries Inc shares fell 18% to $44.70 after reporting preliminary fourth-quarter results below estimates [10]